highly significantp=0.012
8 – 11) A meta-analysis of clinical data in PAD has shown beraprost to achieve a highly significant 39% reduction (p=0.012 vs. placebo) in the risk of systemic vascular events (defined as the events of cardio/cerebrovascular events and exacerbation of leg symptoms). 8) Patients with PAD typically have multiple cardiovascular risk factors, which puts them at markedly increased risk for CV events.